Trading Summary - February 28. Another satisfactory

New Post Public Reply Private Reply Replies (0) Message Board
AJH92
132
Trading Summary - February 28.

Another satisfactory status quo day for $DIGX - on what was a very busy day elsewhere with my #3 long term pick running 50% and mass loading off the bottom at .0001+.0002 on another - whilst we await the anticipated record Q4 results.

The ask at .0004 remained the same at only 4.3M.

As usual there was a ludicrous 10K paint down at .0003 - with no effect of course.

The bid at .0003 was maintained at the increased level of 80M all day (first seen yesterday) - to keep the basher / flippers boxed out from getting any more .0003s.

Another day closer to the PR announcing the provisional 2017 revenue and profits - expected to be a record again - and hopefully also outlining acquisition / growth plans for 2018. In 2017, this PR came out on Feb 28.

Also, before the end of the week we should get another update to the Verified Company Profile confirming no dilution in 2017 and to date in 2018. I'll be looking out for this continuously from now on.

As always, anything could happen at anytime. So stay sharp if you don't already have all the shares you need to make your profit expectations up to Q4 in March 2018 and thereafter throughout 2018.

Prior warning and / or scanner alerts of any significant buys starting a run up will not be given on iHub but they will be alerted here immediately.

Content below the line unchanged from the last update - relevant to those that are new here.

The following items have not been PR'ed yet:

- Shares retired in 2017 (425M known to followers here but not PR'ed yet).

- Excellent 3Q results.

- Provisional 4Q results - including anticipated dramatic increase over 3Q due to additional services now being provided in the chiropractic offices - in Strategic Growth Plan - equipment already acquired at start of Q4).

- Further acquisition plans for brand growth.

In due course, the Q4 results will speak for themselves and - when PR'ed to the wider investing community - we should see serious additional new interest due to the low O/S and relatively high positive revenue for a stock in this price range - just as happened for the 2016 Q4 and the 2017 Q1 and Q2.

The long-term whales who trade $DIGX will continue to buy shares at any price that makes sense to them to use on multiple runs throughout 2018. It is already known from posted comments and observation that at least 4 of the main whales bought shares - on the bid and on the ask - from the impatient at the end of 2017.

As predicted, at least 4 x whales who trade $DIGX continuously throughout each year were happy to take around 100M at .0003 when a few impatient people decided to trade for a loss at .0003 on December 14.

As predicted in October 2017, $DIGX was not allowed to go to the 2016 year-end low of .0002 ask at end-2017.

As predicted, the .0004s were bought out in just 2 individual seconds and the same is likely to happen with the .0005s.at some point - setting off a run towards .0010 - just like happened in 2017 before the first PR.

Any shares bought at .0004 should be worth an easy 150%+ profit on any of numerous runs likely to happen through to Q4. Shares bought at .0005 should easily return 100%+ at some point in 2018.

The big boys in DIGX now probably already have an inventory of 50M>200M each for trading throughout 2018.

Ludicrous claims by the notorious bashers on iHub - "RFB", "munimi", "surfkast:, "Crown Capital" and "Homebrew" - are clearly seen as such by all serious traders and now even by most iHubbers.

Money is not considered "dead" by the most successful traders in the OTC market when they know it will provide a significant return further down the line because they are in a position to understand and influence - through keen observation and record keeping - what volume of shares is likely to be made available for purchase at any particular level.









American EcoFuels Inc (AEFI) Stock Research Links

AEFI Board Company Profile Buy Rating Time & Sales News Filings Financials
"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 62

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 299

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 343

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 29

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 123

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 456

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading

Top 5 Most Recently Viewed Articles

Brazil Potash Secures $75 Million Equity Line for Growth

Updated Category News Views 167

Brazil Potash Secures Key Funding for Autazes Project Brazil Potash Corp. (“Brazil Potash” or the “Company”) (NYSE American: GRO), a prominent player in mineral development focused on potash mining, has recently finalized a significant agreement establishing an equity line of credit (ELOC) with Alumni Capital LP. This collaboration signals a crucial step in...

Continue Reading
AGCO Completes Major Strategic Shift Transforming Business Focus

Updated Category News Views 101

AGCO Completes Divestiture of Grain & Protein Business AGCO Corporation (NYSE: AGCO), a leading firm in agricultural machinery and precision ag technology, has finalized the sale of the majority of its Grain & Protein business to American Industrial Partners (AIP) in an all-cash deal valued at around $700 million. This significant transition emphasizes AGCO's focus on...

Continue Reading
Vincent Bouatou Takes the Helm as CTO at IDEMIA Public Security

Updated Category News Views 64

Vincent Bouatou Appointed as Chief Technology Officer With a wealth of experience in the technology sector, Vincent Bouatou has been officially announced as the Chief Technology Officer (CTO) of IDEMIA Public Security. His extensive background in driving technological innovations positions him to make significant strides in the biometric technology industry. Driving...

Continue Reading
MedX Holdings, Inc. Reaches New Heights in Q1 Revenue Growth

Updated Category News Views 171

MedX Holdings, Inc. Reports Extraordinary Q1 Revenue Gains MedX Holdings, Inc. (OTC: MEDH) is delighted to share its impressive financial results for the first quarter of 2025. With record revenue levels and strategic advancements, this milestone reflects the company's commitment to becoming a prominent player in cannabis retail, technology, and franchise development....

Continue Reading
Erste Group Upgrades WW Grainger Stock Amid Positive Outlook

Updated Category News Views 74

Erste Group upgraded WW Grainger (NYSE: GWW) from Hold to Buy back in mid-2024, showing that the desks had a new favorite. With a return on equity at a whopping 59%, Grainger's performance left many competitors in the dust, making it a must-watch stock for anyone looking to get into industrial supply chains. What's Driving the Upgrade? The reasons behind this rating shift...

Continue Reading